Skip to main content
. 2023 Jan 12;13(1):14. doi: 10.1038/s41408-022-00768-5

Fig. 2. Kaplan–Meier estimates of PFS for patients with high- or standard-risk cytogenetic abnormalities receiving ixazomib- vs placebo-based therapy.

Fig. 2

A High-risk cytogenetic abnormalities, and B standard-risk (complement of high-risk) abnormalities. CI confidence interval, HR hazard ratio, PFS progression-free survival.